{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:48:51Z","timestamp":1780580931458,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH NIGSMS R35","award":["GM131881"],"award-info":[{"award-number":["GM131881"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Osteoporosis affects over 10 million Americans over 50. Bisphosphonate therapy, mainly alendronate, is amongst the most prescribed treatments for the disease. The use of alendronate and other bisphosphonates has been associated with depressive symptoms in recent case reports. In this study we quantified this association by analyzing over 100,000 adverse events reports from the Food and Drug Administration Adverse Events Reporting System (FAERS) and the World Health Organization\u2019s (WHO) global database for adverse drug reactions, ADRs, VigiAccess. We found that alendronate therapy is significantly associated with depression and anxiety when compared to other first-line osteoporosis treatments. The reported risk of depressive ADRs was found to be over 14-fold greater in patients taking alendronate under the age of 65 and over fourfold greater for patients over 65 compared to the control. Several hypotheses concerning the molecular mechanism of the observed association of alendronate and depressive symptoms were discussed.<\/jats:p>","DOI":"10.1038\/s41598-021-03214-x","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T11:03:55Z","timestamp":1639479835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Common osteoporosis drug associated with increased rates of depression and anxiety"],"prefix":"10.1038","volume":"11","author":[{"given":"Dro","family":"Keshishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tigran","family":"Makunts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Abagyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"key":"3214_CR1","unstructured":"54 Million Americans Affected by Osteoporosis and Low Bone Mass. National Osteoporosis Foundation https:\/\/www.nof.org\/news\/54-million-americans-affected-by-osteoporosis-and-low-bone-mass\/."},{"key":"3214_CR2","first-page":"92","volume":"43","author":"KN Tu","year":"2018","unstructured":"Tu, K. N. et al. Osteoporosis: A review of treatment options. Pharm. Ther. 43, 92\u2013104 (2018).","journal-title":"Pharm. Ther."},{"key":"3214_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11914-003-0008-5","volume":"1","author":"AA Reszka","year":"2003","unstructured":"Reszka, A. A. & Rodan, G. A. Mechanism of action of bisphosphonates. Curr. Osteoporos. Rep. 1, 45\u201352 (2003).","journal-title":"Curr. Osteoporos. Rep."},{"key":"3214_CR4","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/ijcp.12022","volume":"66","author":"DA Hanley","year":"2012","unstructured":"Hanley, D. A., Adachi, J. D., Bell, A. & Brown, V. Denosumab: Mechanism of action and clinical outcomes. Int. J. Clin. Pract. 66, 1139\u20131146 (2012).","journal-title":"Int. J. Clin. Pract."},{"key":"3214_CR5","first-page":"499","volume":"2","author":"D Bodenner","year":"2007","unstructured":"Bodenner, D., Redman, C. & Riggs, A. Teriparatide in the management of osteoporosis. Clin. Interv. Aging 2, 499\u2013507 (2007).","journal-title":"Clin. Interv. Aging"},{"key":"3214_CR6","unstructured":"Alendronate Sodium- FDA label [cited 2020 11]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/21575_fosomax_lbl.pdf."},{"key":"3214_CR7","unstructured":"Risedronate- FDA label [cited 2020 11]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020835s048lbl.pdf."},{"key":"3214_CR8","unstructured":"Ibandronate Sodium- FDA label [cited 2020 11]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021455s021lbl.pdf."},{"key":"3214_CR9","unstructured":"Zoledronic Acid- FDA label [cited 2020 11]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021223s041lbl.pdf."},{"key":"3214_CR10","unstructured":"Denosumab- FDA label [cited 2020 11]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125320s195lbl.pdf."},{"key":"3214_CR11","doi-asserted-by":"publisher","first-page":"532","DOI":"10.2146\/ajhp070171","volume":"65","author":"J Stroup","year":"2008","unstructured":"Stroup, J., Kane, M. P. & Abu-Baker, A. M. Teriparatide in the treatment of osteoporosis. Am. J. Health Syst. Pharm. 65, 532\u2013553 (2008).","journal-title":"Am. J. Health Syst. Pharm."},{"key":"3214_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.tem.2009.05.003","volume":"20","author":"G Cizza","year":"2009","unstructured":"Cizza, G., Primma, S. & Csako, G. Depression as a risk factor for osteoporosis. Trends Endocrinol. Metab. 20, 367\u2013373 (2009).","journal-title":"Trends Endocrinol. Metab."},{"key":"3214_CR13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3389\/fpsyt.2019.00200","volume":"10","author":"RR Kelly","year":"2019","unstructured":"Kelly, R. R., McDonald, L. T., Jensen, N. R., Sidles, S. J. & LaRue, A. C. Impacts of psychological stress on osteoporosis: Clinical implications and treatment interactions. Front Psychiatry 10, 200 (2019).","journal-title":"Front Psychiatry"},{"key":"3214_CR14","unstructured":"Bisphosphonates and Depressive Reactions. http:\/\/databankws.lareb.nl\/Downloads\/kwb_2010_4_bisfo.pdf. Accessed 2021."},{"key":"3214_CR15","doi-asserted-by":"publisher","first-page":"8144","DOI":"10.3390\/ijerph18158144","volume":"18","author":"G Martino","year":"2021","unstructured":"Martino, G. et al. Anxiety levels predict bone mineral density in postmenopausal women undergoing oral bisphosphonates: A two-year follow-up. Int. J. Environ. Res. Public Health 18, 8144 (2021).","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"1","key":"3214_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-85389-x","volume":"11","author":"IV Cohen","year":"2021","unstructured":"Cohen, I. V., Makunts, T., Abagyan, R. & Thoman, K. Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database. Sci. Rep. 11(1), 1\u20139. https:\/\/doi.org\/10.1038\/s41598-021-85389-x (2021).","journal-title":"Sci. Rep."},{"key":"3214_CR17","doi-asserted-by":"publisher","first-page":"19199","DOI":"10.1038\/s41598-020-76258-0","volume":"10","author":"IV Cohen","year":"2020","unstructured":"Cohen, I. V., Makunts, T., Moumedjian, T., Issa, M. A. & Abagyan, R. Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports. Sci. Rep. 10, 19199 (2020).","journal-title":"Sci. Rep."},{"key":"3214_CR18","doi-asserted-by":"publisher","first-page":"12851","DOI":"10.1038\/s41598-020-69773-7","volume":"10","author":"T Makunts","year":"2020","unstructured":"Makunts, T., Wollmer, M. A. & Abagyan, R. Postmarketing safety surveillance data reveals antidepressant effects of botulinum toxin across various indications and injection sites. Sci. Rep. 10, 12851 (2020).","journal-title":"Sci. Rep."},{"key":"3214_CR19","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell, R. et al. Pharmacological Management of osteoporosis in postmenopausal women: An Endocrine Society* clinical practice guideline. J. Clin. Endocrinol. Metab. 104, 1595\u20131622 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3214_CR20","first-page":"261","volume":"92","author":"MP Jeremiah","year":"2015","unstructured":"Jeremiah, M. P., Unwin, B. K., Greenawald, M. H. & Casiano, V. E. Diagnosis and management of osteoporosis. Am. Fam. Physician 92, 261\u2013268 (2015).","journal-title":"Am. Fam. Physician"},{"key":"3214_CR21","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman, F. et al. Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos. Int. 25, 2359\u20132381 (2014).","journal-title":"Osteoporos. Int."},{"key":"3214_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown, E. G., Wood, L. & Wood, S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 20, 109\u2013117 (1999).","journal-title":"Drug Saf."},{"key":"3214_CR23","first-page":"35","volume":"147","author":"BH Wolffenbuttel","year":"2003","unstructured":"Wolffenbuttel, B. H. & van der Klauw, M. M. Psychiatric side effects associated with diphosphonate treatment. Ned Tijdschr Geneeskd 147, 35\u201337 (2003).","journal-title":"Ned Tijdschr Geneeskd"},{"key":"3214_CR24","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1073\/pnas.93.7.3068","volume":"93","author":"A Schmidt","year":"1996","unstructured":"Schmidt, A. et al. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: Inhibition by alendronate. Proc. Natl. Acad. Sci. U.S.A. 93, 3068\u20133073 (1996).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"3214_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/mp.2008.131","volume":"15","author":"P Muglia","year":"2010","unstructured":"Muglia, P. et al. Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts. Mol. Psychiatry 15, 589\u2013601 (2010).","journal-title":"Mol. Psychiatry"},{"key":"3214_CR26","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/6866","volume":"21","author":"MJ Wallace","year":"1999","unstructured":"Wallace, M. J. et al. Neuronal defects and posterior pituitary hypoplasia in mice lacking the receptor tyrosine phosphatase PTPsigma. Nat Genet 21, 334\u2013338 (1999).","journal-title":"Nat Genet"},{"key":"3214_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-016-0001-8","volume":"6","author":"JRM Oliveira","year":"2016","unstructured":"Oliveira, J. R. M. & Oliveira, M. F. Primary brain calcification in patients undergoing treatment with the biphosphanate alendronate. Sci. Rep. 6, 1\u20135 (2016).","journal-title":"Sci. Rep."},{"key":"3214_CR28","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake, M. T., Clarke, B. L. & Khosla, S. Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clin. Proc. 83, 1032\u20131045 (2008).","journal-title":"Mayo Clin. Proc."},{"key":"3214_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jns.2005.11.033","volume":"243","author":"JA Loeb","year":"2006","unstructured":"Loeb, J. A., Sohrab, S. A., Huq, M. & Fuerst, D. R. Brain calcifications induce neurological dysfunction that can be reversed by a bone drug. J Neurol Sci 243, 77\u201381 (2006).","journal-title":"J Neurol Sci"},{"key":"3214_CR30","doi-asserted-by":"publisher","first-page":"765","DOI":"10.33549\/physiolres.931121","volume":"56","author":"L Cibickov\u00e1","year":"2007","unstructured":"Cibickov\u00e1, L. et al. Differential effects of statins and alendronate on cholinesterases in serum and brain of rats. Physiol. Res. 56, 765\u2013770 (2007).","journal-title":"Physiol. Res."},{"key":"3214_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","volume":"18","author":"JH Lin","year":"1996","unstructured":"Lin, J. H. Bisphosphonates: A review of their pharmacokinetic properties. Bone 18, 75\u201385 (1996).","journal-title":"Bone"},{"key":"3214_CR32","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1177\/0091270004267594","volume":"44","author":"J Barrett","year":"2004","unstructured":"Barrett, J., Worth, E., Bauss, F. & Epstein, S. Ibandronate: A clinical pharmacological and pharmacokinetic update. J. Clin. Pharmacol. 44, 951\u2013965 (2004).","journal-title":"J. Clin. Pharmacol."},{"key":"3214_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2165\/00003088-199936050-00002","volume":"36","author":"AG Porras","year":"1999","unstructured":"Porras, A. G., Holland, S. D. & Gertz, B. J. Pharmacokinetics of alendronate. Clin. Pharmacokinet. 36, 315\u2013328 (1999).","journal-title":"Clin. Pharmacokinet."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03214-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03214-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03214-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T17:56:57Z","timestamp":1670090217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03214-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3214"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-03214-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,14]]},"assertion":[{"value":"11 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23956"}}